| Jul 2 |
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
|
| Jul 2 |
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
|
| Jul 2 |
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
|
| Jun 4 |
Oppenheimer starts Cartesian at outperform, cites lead drug potential
|
| May 24 |
Mizuho starts Cartesian at buy, cites lead drug asset
|
| May 22 |
Cartesian stock climbs 8% on FDA regenerative therapy designation
|
| May 22 |
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
|
